WCN26-9116 EFFICACY OF PEGCETACOPLAN IN PATIENTS WITH LOWER BASELINE PROTEINURIA: A SUBGROUP ANALYSIS FROM THE VALIANT TRIAL

Read full text Summarise with VIRAT
Authors: Seung Hyeok Han, H J Kang, Nicholas J.A. Webb, Johan Szamosi, Regina Horneff, Katie Gordon, Yiwei Zhang, Eliyahu V. Khankin, Carla Nester
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Conclusion: Clinical efficacy of 52 weeks of pegcetacoplan treatment for adolescents was consistent with the overall population of VALIANT, confirming its sustained benefit in broad patient populations.Previously presented at ASN 2025 (Journal of the American Society of Nephrology) I have potential conflict of interest to disclose.LAG: received research support from Alexion and Apellis; and

Fields of Study & Subjects

Complement system in diseases Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106328–106328
Publication date
25 March 2026
Language
EN